4. Discussion
diarrhea
This study, in 24 healthy adult volunteers (15 females, age 34 years, BMI 22.2 kg/mIn consideration of a “minimal important difference” (MID), which is the smallest difference in the scores that is perceived as significant by the clinician or the patient [The evolutive the GSRS pattern, with tolerability developed over time, therefore underscores the product’s tolerability and safety profile, and is also supported by a previous investigation of oligomalt that found that a 33 g dose was completely metabolized as assessed with a hydrogen breath test over 4 h [Another observation from this study was that there was no clinically meaningful differential effect on stool consistency according to the Bristol Stool Scale. However, the high-dose oligomalt resulted in a slight signal for increase in loose stool, aligned with higher GSRS subdomain diarrhea score. Similar to the tolerability, the Bristol Stool Scale score was subject to a GI adaptation, as indicated by the intervention sequence analysis that found that the stool frequency was numerically lower at the third sequence compared to the first.